Ifosfamide not necessary in chemotherapy for nonmetastatic osteosarcoma
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1J Clin Oncol. 2012 Jun 10;30(17):2112-8. doi: 10.1200/JCO.2011.38.4420. Epub 2012 May 7
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
246 patients with nonmetastatic osteosarcoma were randomized to evaluate the addition of ifosfamide to a primary chemotherapy regimen of methotrexate, cisplatin, and doxorubicin, with patients allocated to chemotherapy with or without ifosfamide. After a median follow-up of 76 months, there was no difference between groups in overall survival, event-free survival, and the percentage of patients wi...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE